301246.SZ深圳证券交易所 · 创业板 ChiNext
Hubei Hongyuan Pharmaceutical 宏源药业
Chemical Pharmaceuticals 化学制药
¥17.10−¥0.57 · −3.23%
Open 开盘
¥17.78
High 最高
¥17.84
Low 最低
¥17.02
Prev Close 昨收
¥17.67
Volume 成交量
553.9万股
Turnover 成交额
¥9,573.2万
Mkt Cap 总市值
¥68亿
P/E 市盈率
24.3×
Recent Activity 近期动态All Filings 全部公告 →
11 significant filings since 31 May 2026: 7 on equity incentive, 2 on new listing and 1 on dividend, and 1 other kind. The latest, on 21 Sep 2026: 董事会薪酬与考核委员会关于2025年限制性股票激励计划预留授予激励对象名单的公示情况说明及核查意见.
自 31 May 2026 起有 11 份重大公告：equity incentive 7 份、new listing 2 份、dividend 1 份，另有 1 类。最新一份（21 Sep 2026）：董事会薪酬与考核委员会关于2025年限制性股票激励计划预留授予激励对象名单的公示情况说明及核查意见。
Price History 价格走势
66 trading days 个交易日 · High 最高 ¥28.94 · Low 最低 ¥17.1417.5020.0022.5025.0027.50
Volume 成交量
1,936.8万
25 Jun17 Jul10 Aug02 Sep24 Sep
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥68亿 | ¥63亿 | 74th highest of 158 · 158 家中第 74 高 | |
| Trailing P/E 市盈率 | 24.3x | 38.4x | 34th lowest of 112 · 112 家中第 34 低 | |
| P/B 市净率 | 1.5x | 2.5x | 26th lowest of 157 · 157 家中第 26 低 | |
| Revenue Growth 营收增速 | 52.1% | 1.6% | 13th highest of 156 · 156 家中第 13 高 | |
| Profit Growth 净利增速 | 2,788.9% | 1.9% | 2nd highest of 158 · 158 家中第 2 高 | |
| Gross Margin 毛利率 | 23.1% | 50.2% | 20th lowest of 155 · 155 家中第 20 低 | |
| Net Margin 净利率 | 11.6% | 9.8% | 67th highest of 157 · 157 家中第 67 高 | |
| Return on Equity 净资产收益率 | 3.4% | 3.1% | 65th highest of 157 · 157 家中第 65 高 | |
| Debt to Assets 资产负债率 | 28.2% | 28.0% | 78th highest of 158 · 158 家中第 78 高 | |
| Grade Score 评级得分 | 56 | 51 | 62nd highest of 157 · 157 家中第 62 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,978亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,952亿 | 38.2x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥693亿 | 73.0x | 14.1x | 54.7% | 27.5% | 18.3% | B |
| Fosun Pharma 复星医药 | ¥621亿 | 18.3x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| CSPC Innovation Pharmaceutical 石药创新 | ¥618亿 | 60.5x | 15.7x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥614亿 | 33.6x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Innocare 诺诚健华 | ¥507亿 | 55.1x | 6.6x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥477亿 | 17.8x | 5.6x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥474亿 | 13.7x | 1.9x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥333亿 | 49.4x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥311亿 | 36.5x | 4.7x | -11.4% | 10.8% | 8.1% | D |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Zelgen 泽璟制药 | ¥284亿 | 51.6x | 16.5x | 220.9% | 53.1% | 45.7% | B |
| Livzon Pharmaceutical Group 丽珠集团 | ¥269亿 | 16.1x | 2.0x | -20.3% | 22.4% | 6.6% | C |
| Hubei Hongyuan Pharmaceutical 宏源药业 | ¥68亿 | 24.3x | 1.5x | 52.1% | 11.6% | 3.4% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。